SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer

Vasey, P.A., Atkinson, R., Osborne, R. et al. (8 more authors) (2006) SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer. British Journal of Cancer, 94 (1). pp. 62-68. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2006 Cancer Research UK. This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Keywords: ovarian cancer; docetaxel; carboplatin; gemcitabine; triple-agent therapy; sequential therapy; quality-of-life; clinical-trials; phase-ii; randomized-trial; paclitaxel; carcinoma; cisplatin; taxanes; toxicity; platinum
Dates:
  • Published: 16 January 2006
  • Published (online): 11 January 2006
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 13 Dec 2016 09:25
Last Modified: 13 Dec 2016 09:31
Published Version: http://dx.doi.org/10.1038/sj.bjc.6602909
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1038/sj.bjc.6602909

Share / Export

Statistics